March 20, 2020 /
Genentech is working with the
U.S. Food & Drug Administration (FDA) to initiate a
randomized, double-blind, placebo-controlled Phase III clinical trial in
collaboration with the Biomedical Advanced Research and Development Authority
(BARDA), a part of the U.S. Health and Human Services Office of the Assistant
Secretary for Preparedness and Response (ASPR), to evaluate the safety and
efficacy of Actemra® (tocilizumab) plus standard of care in hospitalized adult
patients with severe COVID-19 pneumonia compared to placebo plus standard of
care.
U.S. Food & Drug Administration (FDA) to initiate a
randomized, double-blind, placebo-controlled Phase III clinical trial in
collaboration with the Biomedical Advanced Research and Development Authority
(BARDA), a part of the U.S. Health and Human Services Office of the Assistant
Secretary for Preparedness and Response (ASPR), to evaluate the safety and
efficacy of Actemra® (tocilizumab) plus standard of care in hospitalized adult
patients with severe COVID-19 pneumonia compared to placebo plus standard of
care.
…………………………………………………………………………
This article is posted and shared by: #MSViewsandNews
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews
Stay informed with MS news and information - Sign-up here
For MS patients, caregivers or clinicians, Care to chat about MS? Join Our online COMMUNITY CHAT
